Polaryx Therapeutics Inc (PLYX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.80+4.05%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PLYX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PLYX — officer change
Dated 2026-07-21
Chief Medical Officer — Lisa Bollinger, MD: Dr. Lisa Bollinger resigned from her position as Chief Medical Officer.
Why it matters: The May financing was said to fund operations through Q2 2027. Cash updates will show whether the trial can reach planned milestones.
Watch forA company update confirms cash is expected to fund operations through at least June 30, 2027. No new financing is needed.
Also watch forA company update puts the runway before June 30, 2027, or announces new financing to fund planned work.
Why it matters: The next earnings date is a near-term chance to hear whether the Q4 trial start remains on track and cash still covers planned work.
Watch forOn November 12, Polaryx confirms the Q4 2026 SOTERIA start is on track. The stated Q2 2027 runway remains intact.
Also watch forOn November 12, Polaryx reports a delayed trial start or a cash runway ending before Q2 2027.
Why it matters: Enrollment would show that the trial is moving beyond its launch. The four groups are CLN2, CLN3, Krabbe disease, and Sandhoff disease.
Supportive ifPolaryx reports that patients have enrolled in all four SOTERIA disease groups.
Worry ifPolaryx reports that one or more planned groups have no enrolled patients, or that enrollment is paused.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$245 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $2,163 loss on $10,000 · 21.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,506 loss on $10,000 · 95.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.